echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > PwC: Q1 2018 venture capital report of biopharmaceutical industry

    PwC: Q1 2018 venture capital report of biopharmaceutical industry

    • Last Update: 2018-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: according to the latest moneytree quarterly report jointly produced by Sina Pharmaceutical Co., Ltd and CB insights on April 16, 2018, venture capital in the biopharmaceutical industry began to show a trend of decreasing transaction volume but increasing transaction volume at the beginning of the year According to the report, in the first quarter of this year, the biopharmaceutical industry completed a total of 39 venture investments, raising US $4.011 billion Compared with the same period last year, the total number of transactions decreased by 22%, and the total number of transactions increased by 37%; compared with the last quarter, the total number of transactions decreased by 28%, and the total number of transactions increased by 11% According to the report, in the first quarter of 2018, pure biotechnology companies ranked first in the financing of biopharmaceutical risks with a total amount of USD 1.922 billion, accounting for nearly half (48%) of the total financing The second is drug development company (US $1.105 billion), accounting for 27.5% of the total financing; the second is drug discovery company (US $43846 million), disease diagnosis company (US $2636.6 million), drug delivery company (US $16733 million), drug production company (US $46.28 million), drug / drug company (US $38.5 million), beauty medicine company (US $30.94 million) In the "healthcare" category, biopharmaceuticals accounted for seven of the top 10 transactions with a transaction value ≥ US $100 million, according to the report 1 Financing amount of Moderna therapeutics: US $500 million announcement time: February 1, 2018 introduction: Moderna therapeutics was founded in 2011, focusing on the development of innovative therapeutic drugs and vaccine products based on mRNA The company is the forerunner of mRNA drug development, and the created mRNA technology platform is a new in vivo drug model, which can produce therapeutic proteins or antibodies in patients' cells, and is expected to provide a superior alternative to the existing protein drug model for a wide range of diseases Since its establishment, modern has established the industry-leading mRNA technology platform and rich pipeline assets At present, there are 19 kinds of drugs under research, 10 of which have entered human clinical practice, with indications covering oncology, rare diseases, cardiovascular, infectious diseases and other fields This round of financing is equity financing The funds will be used to further promote the transformation of R & D into mRNA pipeline assets, promote the clinical development of 19 existing candidate drugs, promote the development of innovative drug discovery and preventive vaccine in the field of rare diseases, and continue to invest in mRNA science and technology to further promote the development of mRNA technology platform In this financing, new venture capital institutions include: a wholly-owned subsidiary of adia, EDBI in Singapore, BB biotech AG, Baosheng bank in Switzerland and Sequoia Capital China 2 Viela bio financing amount: US $250 million announcement time: February 28, 2018 introduction: viela bio is a biopharmaceutical company separated from MedImmune, global biological product R & D Department of AstraZeneca, focusing on the field of inflammation and autoimmune diseases Viela bio has obtained three preclinical candidate drugs and three new drugs under clinical research from MedImmune, of which inebilizumab is the fastest advancing drug Currently, it is in phase IIB clinical development for the treatment of neuromyelitis optica (NMO) The drug has obtained orphan drug qualification in the United States and the European Union The financing is round a, and the funds will be used to complete the phase II clinical work of inebilizumab, develop early stage drugs and continue to explore innovative therapies in the field of inflammation and autoimmune diseases A consortium of Tonghe Yucheng, Boyu capital and Hillhouse capital led this round of investment In addition, Temasek and SIRONA capital also participated in this round of investment After the financing, AstraZeneca remains the largest minority shareholder of viela bio 3 Celularity financing amount: US $250 million announcement time: February 19, 2018 introduction: celularity is separated from the new base, with independent research and development of cutting-edge technology and intellectual property rights using placenta power The company's product development is an innovative biotechnology platform based on placental stem cells, which can avoid ethical disputes on embryonic stem cells Because placenta contains nearly ten times more stem cells than cord blood, its economic potential is immeasurable At present, celularity's medical portfolio includes wound bioremediation products, immunotherapy adjuvants, allogeneic car-t / NK products, placental cell therapy products, etc., and holds more than 800 placental stem cell patents The company plans to use this round of financing funds to accelerate the commercialization of allogeneic cell and tissue regeneration therapy from the placenta after childbirth, so as to solve the vast unmet medical needs such as cancer, chronic diseases and degenerative diseases This round of financing is led by Xinji 4 Helix financing amount: US $200 million announcement time: March 1, 2018 introduction: helix is separated from the global gene sequencing giant Illumina, focusing on personal genomics services, using the new generation of gene sequencing technology (NGS) to sequence exons of customers In July 2017, helix launched the first online genomics app store in history, which is believed to usher in a new era of consumer genomics The financing is round B, and the funds will be used to develop innovative health products based on ngs and promote the revolution of personal genomics This round of financing is led by DFG growth fund, with the participation of Illumina, Kleiner Huaying, Mayo Clinic, Sutter Hill venture capital and Warburg Pincus 5 Tcr2 therapeutics financing amount: 125 million US dollars announcement date: March 21, 2018 introduction: tcr2 therapeutics is a new cutting-edge tumor immunotherapy company located in Boston area of the United States, focusing on the development of innovative T-cell therapy, the treatment of solid tumors and blood cancer The company's unique T cell receptor (TCR) platform can reprogram the natural TCR complex, which is expected to kill cancer cells quickly and permanently, and maintain low cytokine release In addition, such innovative technologies can allow T cells to recognize tumor cells without HLA matching In preclinical trials, TCR showed better activity in many solid tumors than car-t The financing is round B, and the funds will be used to promote two truc T cell projects to pass the human body concept verification, including the leading solid tumor project tc-210, and further expand the company's multi version truc platform, including double target truc, immune cell enhancement and allogeneic technology The leading institutions of this financing are Tonghe Yucheng and cultural ventures 6 Tmunity therapeutics financing amount: US $100 million announcement date: January 23, 2018 introduction: tmunity therapeutics is a biotechnology company located in Philadelphia, USA, which is committed to developing a safer and more effective new generation of T-cell immunotherapy to treat solid tumors and hematological system tumors Tmunity has established a wide range of exclusive cooperation with the University of Pennsylvania and the University of Minnesota, integrating the most cutting-edge technology At the same time, tmunity has a highly respected founder team in the industry Its CEO and President, Dr Usman "Oz" Azam, was once the leader of Novartis cell and gene therapy The financing is round a, and the funds will be used to expand the business and operation structure of the company and support the transformation research, development and production of innovative T-cell-based immunotherapy The investors involved in this round of financing include Ping An venture capital in China, Parker cancer immunotherapy center, Gilead, be the match, University of Pennsylvania and Lilly Asia Fund 7 Gossamer bio financing amount: US $100 million announcement date: January 4, 2018 introduction: gossamer bio was founded by the former executive team of receptos company, focusing on the discovery and development of new and differentiated treatment products The company's strategy is to leverage the current environment with rich R & D resources and active R & D authorization, focus on treatment innovation in immunology, inflammation, fibrosis, tumor and other fields, and solve the high unmet medical needs in these fields The financing is round a financing, and the funds raised will be used for the preparation of the company, and to promote the early and later clinical development of several candidate drugs and expand the establishment of R & D pipeline The details have not been disclosed This financing is jointly led by arch venture partners and Omega funds, a seed round investor.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.